Welcome to the e-CCO Library!

search
Search by: 
Year: Category: Sub Type:
DOP37: Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Silvio Danese
Created: Friday, 14 July 2023, 2:22 PM
DOP37: Neoplastic lesions outside diseased area in Inflammatory Bowel Disease patients: A National Cohort Study
Year: 2020
Source: ECCO'20 Vienna
Authors: Anneline Cremer
Created: Tuesday, 23 June 2020, 5:40 PM
DOP37: Noninvasive assessment of gut function using transcriptional recording sentinel cells
Year: 2024
Source: ECCO'24 Stockholm
Authors: Zimmermann, Jakob
Created: Tuesday, 30 April 2024, 5:03 PM
DOP38: A rare KRT17+ population emerges from the epithelium in the inflamed intestinal mucosa of patients with Ulcerative Colitis
Year: 2024
Source: ECCO'24 Stockholm
Authors: Dotti, Isabella
Created: Tuesday, 30 April 2024, 5:03 PM
DOP38: Prevalence of fatigue in a severe Inflammatory Bowel Disease cohort highly exposed to biologics
Year: 2020
Source: ECCO'20 Vienna
Authors: Claire Liefferinckx
Created: Tuesday, 23 June 2020, 5:40 PM
DOP38: Upadacitinib Therapy Reduces Crohn’s Disease Symptoms Within the First Week of Induction Therapy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Jean-Frédéric Colombel
Created: Friday, 14 July 2023, 2:22 PM
DOP39: Constructing butyrate-producing yeast as a cell-dependent treatment option for Inflammatory Bowel Disease
Year: 2024
Source: ECCO'24 Stockholm
Authors: Wu, Jiahao
Created: Tuesday, 30 April 2024, 5:03 PM
DOP39: Endoscopic, histologic, and combined outcomes with reinitiation of ozanimod after temporary discontinuation: 2-year interim analysis of the True North open-label extension study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Séverine Vermeire
Created: Friday, 14 July 2023, 2:22 PM
DOP39: The first prospective, mucticentre, randomised controlled trial on discontinuation of infliximab in Ulcerative Colitis in remission; endoscopic normalisation does not guarantee successful withdrawal
Year: 2020
Source: ECCO'20 Vienna
Authors: Taku Kobayashi
Created: Tuesday, 23 June 2020, 5:40 PM
DOP40: Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Marla C Dubinsky
Created: Friday, 14 July 2023, 2:22 PM
DOP40: Does levels of concerns and expectations predict IBD disease status?
Year: 2020
Source: ECCO'20 Vienna
Authors: Valérie Pittet
Created: Tuesday, 23 June 2020, 5:40 PM
DOP40: Inflammatory Bowel Disease single cell atlas construction to enable cell type-specific target identification
Year: 2024
Source: ECCO'24 Stockholm
Authors: Corridoni, Daniele
Created: Tuesday, 30 April 2024, 5:03 PM
DOP41: Achievement of corticosteroid-free clinical endpoints in subjects with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Stefan Wolfgang Schreiber
Created: Friday, 14 July 2023, 2:22 PM
DOP41: Low grade dysplasia prognosis and predictive factors for advanced neoplasia progression in the 21st century – a large multi-centre retrospective cohort study
Year: 2020
Source: ECCO'20 Vienna
Authors: Misha Kabir
Created: Tuesday, 23 June 2020, 5:40 PM
DOP41: Mucosal single-cell profiling of Crohn's-like disease of the pouch reveal unique pathogenesis and therapeutic targets
Year: 2024
Source: ECCO'24 Stockholm
Authors: Deepak, Parakkal
Created: Tuesday, 30 April 2024, 5:03 PM
DOP42: Efficacy of etrasimod on symptomatic relief in patients with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Maria Chaparro
Created: Friday, 14 July 2023, 2:22 PM
DOP42: Impact of discontinuing thiopurines at anti-TNF initiation in Inflammatory Bowel Disease: A nationwide Danish cohort study
Year: 2020
Source: ECCO'20 Vienna
Authors: Sandra Bohn Thomsen
Created: Tuesday, 23 June 2020, 5:40 PM
DOP43: Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Axel Dignass
Created: Friday, 14 July 2023, 2:22 PM
DOP43: Histologic improvement, attenuation of inflammation and microbiome modulation by engineered high acetate producing Saccharomyces boulardii in DSS-induced colitis
Year: 2024
Source: ECCO'24 Stockholm
Authors: Deleu, Sara
Created: Tuesday, 30 April 2024, 5:03 PM
DOP43: The risk of extra-intestinal cancer in Inflammatory Bowel Disease (IBD): A systematic review and meta-analysis of population-based cohort studies
Year: 2020
Source: ECCO'20 Vienna
Authors: Bobby Zhao Sheng Lo
Created: Tuesday, 23 June 2020, 5:40 PM